Loading quotes...

Forecast

The analysts' average price target is €163.31 (-1.26%). The median is €152.54 (-7.78%).

Buy	22
Hold	2
Sell	0

News Go to news feed

Repligen raises forecast and expects growth boost from BioLife takeover

At the Wells Fargo conference, Repligen reported broader-based growth despite headwinds in areas such as gene therapy and ATF customers. The company said Q2 organic growth was 13% (14% before duty refunds), raised its full-year guidance to 10.5–13.5%, and cited adjusted core growth of about 16%. Management sees drivers in Protein A resins, process analytics, chromatography, a recovery in China/APAC, and opportunities in mRNA, cell therapies and AI-supported instruments. The planned acquisition of BioLife Solutions is expected to deliver economies of scale, lift synergies by $20 million in the first year, and support the path to $1 billion in revenue by 2027 and a 30% EBITDA margin by 2030. » More on de.investing.com
Repligen raises annual forecast and buys BioLife for $1.5 billion

Repligen reports significantly better-than-expected quarterly figures with strong order intake. The company has raised its full-year outlook and plans to acquire BioLife for $1.5 billion. Analysts therefore view Repligen as an established market leader in the growing biopharma segment, sparking increased interest from institutional investors. » More on finanzen.net
Repligen: $100 investment 10 years ago would have grown 391%

A $100 investment in Repligen ten years ago would today have resulted in 3.339 shares and be worth $491.02, based on a price of $147.06 on August 3, 2026. That corresponds to a gain of 391.02 percent. Repligen’s market capitalization was most recently $7.97 billion. Stock splits and dividends are not included in the calculation. » More on finanzen.net

Financials

In the last quarter, RepliGen had revenue of €178.86m and net profit of €4.39m

(EUR)	June 2026	YoY
Revenue	178.86m	15.60%
Gross profit	94.94m	22.78%
Net profit	4.39m	65.21%
EBITDA	40.24m	1.88%

Fundamentals

Metric	Value
Market capitalization	€10.26bn
Number of shares	63.49m
52-week high/low	€178.44 - €90.62
Dividends	No
Beta	1.08
P/E ratio	243.47
PEG ratio	0.30
P/B ratio	4.81
P/S ratio	14.57

Company profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.